How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation by Maschmeyer, G. & Donnelly, J.P.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/172706
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
How to manage lung infiltrates in adults suffering from
haematological malignancies outside allogeneic haematopoietic
stem cell transplantation
Georg Maschmeyer1 and J. Peter Donnelly2
1Department of Haematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany and 2Department of
Haematology, Radboud University Medical Centre, Nijmegen, The Netherlands
Summary
Pulmonary complications affect up to 40% of patients with
severe neutropenia lasting for more than 10 d. As they are
frequently associated with fever and elevation of C-reactive
protein or other signs of inflammation, they are mostly han-
dled as pneumonia. However, the differential diagnosis is
broad, and a causative microbial agent remains undetected in
the majority of cases. Pulmonary side effects from cytotoxic
treatment or pulmonary involvement by the underlying
malignancy must always be taken into account and may pro-
vide grounds for invasive diagnostic procedures in selected
patients. Pneumocystis jirovecii (in patients not receiving co-
trimoxazole as prophylaxis), multi-resistant gram-negative
bacilli, mycobacteria or respiratory viruses may be involved.
High-risk patients may be infected by filamentous fungi, such
as Aspergillus spp., but these infections are seldom proven
when treatment is initiated. Microorganisms isolated from
cultures of blood, bronchoalveolar lavage or respiratory
secretions need careful interpretation as they may be irrele-
vant for determining the aetiology of pulmonary infiltrates,
particularly when cultures yield coagulase-negative staphylo-
cocci, enterococci or Candida species. Non-culture based
diagnostics for detecting Aspergillus galactomannan, beta-D-
glucan or DNA from blood, bronchoalveolar lavage or tissue
samples can facilitate the diagnosis, but must always be inter-
preted in the context of clinical and imaging findings. Sys-
temic antifungal treatment with mould-active agents, given
in combination with broad-spectrum antibiotics, improves
clinical outcome when given pre-emptively. Co-trimoxazole
remains the first-line treatment for Pneumocystis pneumonia,
while cytomegalovirus pneumonia will respond to ganciclovir
or foscarnet in most cases. The clinical outcome of acute res-
piratory failure can also be successful with proper intensive
care, when indicated.
Keywords: lung infiltrates, pneumonia, neutropenia, fever,
diagnosis.
Epidemiology of pulmonary complications in
patients with haematological malignancies
Respiratory symptoms or signs such as dyspnoea, cough,
sputum, chest pain, rales, haemoptysis, impaired oxygenation
and/or pulmonary infiltrates on chest radiographs (CXR) or
computerized tomography (CT) scans are frequent among
patients with haematological malignancies (HM). Up to 30%
of patients undergoing chemotherapy for acute leukaemia
may be affected (Chaoui et al, 2004; Garcia et al, 2013), par-
ticularly those with pre-existing pulmonary disease and those
who smoke. Around 12–15% of severely neutropenic patients
with first fever will present with lung infiltrates (LI) (Masch-
meyer et al, 1994), and half of patients without abnormalities
on CXR, who remain febrile after at least 48 h of broad-
spectrum antibacterial treatment, will show LI on pulmonary
CT scans (Heussel et al, 1999). Respiratory complications are
also frequent among patients with chronic lymphocytic leu-
kaemia, and often run a complicated clinical course due to
the complex immunodeficiency. Respiratory events (RE)
affect less than 1 in 10 of autologous stem cell transplant
recipients (Reich et al, 2001). However, this proportion may
be as high as 15%, particularly among patients with myeloma
who experience 7 or more days of severe neutropenia with a
substantial associated mortality.
Typically, publications on the causes of LI are based upon
clinical data, imaging procedures and microbiological findings.
Garcia et al (2013) retrospectively analysed the clinical course
of over 800 patients undergoing chemotherapy for acute
myeloid leukaemia (AML; n = 645), acute lymphoblastic leu-
kaemia (ALL; n = 121) or high-risk myelodysplastic syndrome
(MDS; n = 35) undergoing chemotherapy at their institu-
tion between 2005 and 2009. They found a pre-treatment
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prevalence of pneumonia of 11% and the occurrence of pneu-
monia in further 21%, with an overall fatality rate of 17%. The
cumulative incidence was highest among patients with MDS
(294%) and intermediate in AML patients (216%). Patients
with pneumonia also had a much higher overall 33-d mortality
(>20%) than did those without pneumonia (<5%).
In a small series of 65 patients with de novo or secondary
acute leukaemias, Chaoui et al (2004) identified 30 (46%)
with respiratory events. Cardiac failure was the predominant
non-infectious cause, while aspergillosis and bacterial pneu-
monia due to gram-negative bacilli were the main causes of
LI with an infectious origin. The majority of RE occurred
within 10 d of leukaemia diagnosis, and the outcome of the
affected patients was significantly poorer than for those
patients without RE (Chaoui et al, 2004).
Over 9 years, RE among patients with chronic lympho-
cytic leukaemia was associated with a poor prognosis and a
fatality rate of 40% (Ahmed et al, 2003). A quarter of these
complications were not caused by pneumonia, but by pleural
effusion or lung infiltration by the underlying malignancy
(9%), pulmonary leucostasis (4%), secondary malignancies,
aggressive transformation (Richter syndrome) (3%) or bron-
chial obstruction (2%). With respect to prognosis, granulocy-
topenia and renal failure had an unfavourable impact on
clinical outcome.
Histopathological findings are only available in a minority
of cases, and may show a variety different causes of LI,
including fungi, alveolar bleeding, infiltration by the underly-
ing malignancy, cryptogenic organizing pneumonia, immune
reconstitution syndrome and lung damage from chemother-
apy or radiation (Shorr et al, 2004; Camus & Costabel,
2005). Drug-induced LI should also be kept in mind, how-
ever, only a small number of chemotherapeutic agents are
likely to cause LI among the febrile neutropenic patients
discussed here, e.g., all-trans retinoic acid (ATRA), BCNU
(carmustine), bleomycin, cyclophosphamide, high-dose cyto-
sine arabinoside, etoposide, gemcitabine, fludarabine,
melphalan or methotrexate.
Lung infiltrates due to leucostasis or leukaemic
infiltration of the lungs
Some newly diagnosed acute leukaemia patients present with
fever and LI, occasionally requiring immediate intensive care
(Chaoui et al, 2004; Darmon et al, 2005). These patients are
particularly challenging, because it is unclear if the infiltrates
are due to pulmonary involvement of leukaemia or to an
infection resulting from the underlying immunosuppression
(Koh et al, 2005). In cases where an informative lung biopsy
(or autopsy) has been obtained, leukaemic infiltration along
the lymphatics in the peribronchovascular, septal, and pleural
interstitial tissue represents the typical pattern (Koh et al,
2005), and the majority of patients affected do not have pul-
monary leucostasis caused by hyperleucocytosis (Potenza
et al, 2003). An acute lysis pneumopathy associated with
diffuse alveolar damage may occur during or shortly following
the initiation of cytotoxic chemotherapy (Tryka et al, 1982).
ATRA syndrome (differentiation syndrome)
The differentiation syndrome in patients with acute promye-
locytic leukaemia (APL) treated with all-trans retinoic acid
(ATRA syndrome) will not be addressed here in detail. It
may be associated with fever in up to 80% of patients, but
does not typically occur in the setting of fever and severe
neutropenia (Luesink & Jansen, 2010). It is primarily
induced by chemokines released from differentiating APL
cells and is not managed with antimicrobial therapy, but glu-
cocorticosteroids.
Lung infiltrates in severely neutropenic patients with
fever
Lung infiltrates may be found in up to 30% of febrile neu-
tropenic patients. Conventional CXR of patients with first
fever in neutropenia may miss LI, while pulmonary CT scans
obtained under the same circumstances most probably will
show LI in a larger proportion of patients (Heussel et al,
1999). These LI are more likely to prove fatal as compared
with other documented infections in febrile neutropenic
patients (Maschmeyer et al, 1994) and their treatment is
more complex and costly (Kuderer et al, 2006; Garcia et al,
2013). Clinical outcome deteriorates with increasing patient
age and is particularly dismal for patients with bacteraemia
and shock, especially when appropriate antimicrobial treat-
ment is delayed (Carratala et al, 1998).
A favourable clinical response to antibacterial treatment is
achieved in less than 1 in 3 patients with pulmonary infil-
trates during febrile neutropenia (Maschmeyer et al, 1994;
Raad et al, 1996) with a high fatality rate (Al Ameri et al,
2010), while the addition upfront of mould-active systemic
antifungals, such as amphotericin B or voriconazole,
increases the response rate to up to 78% (Schiel et al, 2006).
Additional findings indicate that the majority of LI among
severely neutropenic patients are caused by filamentous
fungi, particularly Aspergillus spp., including a reduction in
the incidence of LI in a small study of voriconazole prophy-
laxis in patients with acute leukaemia (Vehreschild et al,
2007), histopathological and molecular findings (Lass-Fl€orl
et al, 2007) and autopsy studies (Chamilos et al, 2006).
Lung infiltrates among patients who have been treated
with nucleoside analogues, such as fludarabine, may involve
a range of microorganisms, such as cytomegalovirus,
mycobacteria or yeasts, that are more typically observed dur-
ing prolonged T cell suppression (Samonis & Kontoyiannis,
2001) as well as Staphylococcus aureus, Pseudomonas aerugi-
nosa, Aspergillus spp. and pneumococci (Ahmed et al, 2003).
Respiratory viruses, including Influenza A and Respiratory
Syncytial Virus (RSV), have occasionally been identified as
causes of pulmonary infiltrates in hospitalized, febrile
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neutropenic adults (Martino et al, 2003), predominantly dur-
ing wintertime. However, at least during febrile neutropenia,
virological diagnostic tests are seldom ordered because of
uncertainty about their relevance and the lack of effective
agents to treat these infections. The vast majority of RSV
infections occur among haematopoietic stem cell transplant
recipients, while reports on viral pneumonia in other patients
mainly involve out-patients and show conflicting results with
regard to their clinical importance (Lehners et al, 2013).
Human metapneumovirus (hMPV) was identified in the
early 2000s and affects up to 9% of adult patients with HM
and symptoms of respiratory tract infection (Williams et al,
2005), but the outcome tends to be favourable despite the
absence of effective anti-hMPV antivirals (Godet et al, 2014).
However, a recent outbreak of pulmonary hMPV infections
among haematology patients was associated with fatality rate
of 4 out of 15 patients (27%) (Hoellein et al, 2015).
What imaging technique should I order?
Conventional CXR show abnormalities in less than 2% of
febrile neutropenic patients who have no obvious clinical
signs or symptoms lower respiratory tract infection (Navi-
gante et al, 2002; Oude Nijhuis et al, 2003). It is not unrea-
sonable to assume that many more of these patients would
have abnormalities detected on CT scans, but no prospective
randomized studies to compare the yield of CT scan versus
CXR have been conducted. However, among neutropenic
patients with fever persisting despite more than 48 h of
broad-spectrum antibacterial therapy, only about 10% of
CXR show abnormalities, while high-resolution CT scans
taken at the same time show pathological findings in approx-
imately 50% of patients (Heussel et al, 1999). Abnormalities
seen on CXR indicate a CT scan should be done to more
specifically identify the most likely aetiology. Hence, a CXR
is of very limited value, as a pulmonary CT scan (without
contrast media) must be ordered anyway as soon as possible,
preferably as part of the investigation of fever during neu-
tropenia.
Is the pattern of lung infiltrates on pulmonary
CT scans informative for differential diagnosis?
Detecting LI on CT scan has three prognostically important
consequences:
• The early detection of lesions indicating invasive mould
disease or Pneumocystis pneumonia (PcP) facilitates tar-
geted bronchoalveolar lavage (BAL) and prompt institu-
tion of pre-emptive antimicrobial treatment, resulting in
improved survival of these patients (Guo et al, 2014);
• CT findings, such as consolidation, small nodules with or
without a typical or reversed ‘halo sign’ and ‘air-crescent
sign’, may be important signs of filamentous fungal
disease. The ‘halo sign’, i.e., a dense nodular infiltrate
surrounded by an area of ground-glass opacity represent-
ing an infarction and a haemorrhage, has been described
as characteristic for neutropenic patients with invasive
pulmonary aspergillosis (IPA) (Bruno et al, 2007). The
‘reversed halo sign’, showing a focal rounded area of
ground-glass opacity surrounded by a crescent or complete
ring of consolidation, has been reported to be relatively
specific for fungal pneumonia due to mucormycosis
(Georgiadou et al, 2011; Legouge et al, 2014). However, it
also may also be associated with other lung diseases, such
as tuberculosis, sarcoidosis, or cryptogenic organizing
pneumonia (Godoy et al, 2012);
• The pattern of LI on the CT scan may also help to distin-
guish fungal from other aetiologies of LI (Caillot et al,
1997; Heussel et al, 2004). PcP typically causes diffuse per-
ihilar infiltrates, areas of ground-glass attenuation, cysts
and septal thickening, consolidation and centrilobular nod-
ules (Kanne et al, 2012; Vogel et al, 2012). However, this
‘classical PcP pattern’ has also been described for LI from
acute leukaemia (Potenza et al, 2003). Nodular or cavitary
lesions indicate an invasive ‘mould’ disease, while differen-
tial diagnoses include pneumonia caused by other
microorganisms, such as mycobacteria (in patients from
high prevalence areas), Nocardia, Pneumocystis jirovecii or
Pseudomonas aeruginosa and infiltrates by the underlying
malignancy (Shorr et al, 2004).
Combining CT scan with angiography has been reported
to increase the diagnostic specificity in some cases with sus-
pected pulmonary mould diseases (Stanzani et al, 2015),
because vessel occlusion is better seen than with native scans.
However, this procedure is not only more labour-intensive,
but is also more burdensome for the patients due to the use
of contrast media, and its added value to other CT findings
has not yet been established. Magnetic resonance tomography
(MRI) may be an alternative to a CT scan, but it appears to
be inferior to CT in visualizing ground-glass opacities
(Attenberger et al, 2014).
Follow-up CT scans should usually only be ordered after
at least 7 d have elapsed after starting antimicrobial therapy,
because otherwise, the course of LI may be misinterpreted.
Patients with invasive pulmonary aspergillosis may show
increasing LI volumes during the first week despite effective
antifungal therapy (Caillot et al, 2001). This may create a
false impression that the current antifungal medication is
ineffective and should be changed. A regression of the ‘halo’
sign and the appearance of an ‘air-crescent’ sign, however,
usually indicate a favourable response (Brodoefel et al,
2006).
Can I make a microbiological diagnosis? How
useful is it to order a prompt bronchoscopy?
The microbiological aetiology is never established in the
majority of febrile neutropenic patients with LI. Microbiolog-
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ically documented cases are frequently based upon findings
from bronchial secretions or BAL fluid and even blood cul-
tures obtained contemporaneously. The diagnostic relevance
of these culture results, however, is often difficult to assess
(Boersma et al, 2007; Azoulay et al, 2008), because bronchial
samples from these patients may contain microorganisms
that have no aetiological significance, such as Candida spe-
cies, coagulase-negative staphylococci, viridans streptococci
and enterococci. Moreover, bacteraemia due to these bacteria
seldom, if ever, results in pneumonia. At the same time, as
many as 3 of 4 cases of invasive fungal disease found at
autopsy had not been detected ante mortem (Chamilos et al,
2006). By contrast, isolation of Aspergillus spp. or other fila-
mentous fungi from oropharyngeal or upper respiratory tract
specimens from severely immunocompromised patients is
regarded as a sign of pulmonary mould infection (Perfect
et al, 2001).
The importance of bronchoscopy and BAL among febrile
neutropenic patients with LI is controversial. The diagnostic
yield is low and the clinical outcome of these patients has
not yet been shown to be improved by invasive diagnostic
procedures including BAL (Azoulay et al, 2010). However, a
detection rate of 25% has been reported for potential patho-
gens in BAL samples from patients with cancer (Jain et al,
2004; Boersma et al, 2007), with bacteria accounting for
about a third of them, P. jirovecii for 15% among patients
not receiving co-trimoxazole prophylaxis, and filamentous
fungi, predominantly Aspergillus spp., for 5–10%. There is no
diagnostic ‘gold standard’ (as biopsy is seldom justified) so it
is impossible to estimate the number of false-positive and
false-negative findings in BAL samples, and the benefit or
failure of ‘pathogen-directed’ antimicrobial treatment there-
fore remain obscure. A list of microorganisms that should
generally be regarded as irrelevant for the aetiology of LI is
given in Table I.
Do non-culture based diagnostic methods
(antigen detection, polymerase chain reaction)
help?
Cytomegalovirus (CMV) and respiratory viruses
Respiratory viruses may be the cause of LI among patients
with profound cellular immunosuppression, so BAL and
nasopharyngeal and oral swabs should include investigations
for CMV, Influenza, Parainfluenza, RSV, Coronavirus, Rhi-
novirus and hMPV (Williams et al, 2005; Hirsch et al, 2013).
CMV polymerase chain reaction (PCR) is recommended for
BAL samples from febrile neutropenic patients with LI, as
the test has a high negative predictive value, so CMV can be
excluded. However, the positive predictive value is low
(Hohenthal et al, 2005), so rapid culture, immediate early
antigen, direct fluorescent antibody tests, DNA hybridization
or cytology is required to confirm the diagnosis of CMV
pneumonia (Boeckh, 2011).
Pneumocystis jirovecii
Microscopy has been the classical reference method for
detecting P. jirovecii, but this has largely been replaced by
PCR for early detection is it exhibits high sensitivity. It is
essential to distinguish infection from colonization as this
may affect over half of individuals without any signs or
symptoms of PcP (Ponce et al, 2010). Meta-analysis of PCR
showed the test to exhibit both high sensitivity (99%) and
specificity (90%) (Lu et al, 2011). Hence, a negative test
result on a BAL sample indicates that anti-Pneumocystis
therapy is unnecessary. More recently, quantitative PCR
assays have been shown to boost the specificity. A report on
non-HIV 71 patients with proven PcP showed a positive pre-
dictive value of 98% when more than 1450 organisms per ml
were detected in BAL samples (M€uhlethaler et al, 2012),
however, this threshold has not yet been prospectively evalu-
ated in clinical studies, and in individual patients with severe
PcP, a much lower copy number may be present. Determin-
ing beta-D-glucan in serum can also help in the differential
diagnosis, because a negative result effectively rules out a
diagnosis of PcP (Karageorgopoulos et al, 2013).
Filamentous fungi
Numerous methods have been developed for detecting fungal
cell antigens, such as Aspergillus galactomannan (GM), 1,3-
beta-D-glucan and nuclear amplification assays including
PCR, to identify fungal DNA for the early detection of fila-
mentous fungi in febrile neutropenic patients with LI of
undetermined aetiology (Maertens et al, 1999; Spiess et al,
2003). Currently, an optical density (OD) index >05 from
blood samples is regarded as the threshold for detecting GM,
whereas a cut-off of ≥10 is more appropriate for BAL
Table I. Microbiological findings generally not aetiologically relevant
for lung infiltrates.
1 Any microorganism isolated from skin, faeces or urine cultures*
2 From any specimen
i Coagulase-negative staphylococci
ii Viridans streptococci
iii Enterococci
iv Coryneform bacteria
3 Isolates from specimens from skin, saliva, sputum or tracheal
aspirates
i Candida spp.†
*Recent recovery, by culture of highly resistant bacteria, such as
extended-spectrum beta-lactamase producing gram-negative bacilli,
may have an impact on the selection of the appropriate antibacterial
agent.
†Candida spp. isolated from skin biopsies of septic patients indicates
invasive candidiasis, which may be associated with haematogeneous
dissemination to the lungs.
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samples (Zou et al, 2012), as this indicates probable invasive
fungal disease in severely immunocompromised patients.
Whether Aspergillus GM will be detected in blood earlier
than finding suggestive infiltrates in a chest CT scan is con-
tentious (Weisser et al, 2005). The GM test is also prone to
yield false-positive results in blood samples obtained from
patients treated with semisynthetic beta-lactam antibiotics,
such as amoxicillin-clavulanate, piperacillin-tazobactam, car-
bapenems, ceftriaxone or cefepime (Boonsarngsuk et al,
2010), those given enteral nutrition (Girmenia et al, 2011)
and those with other fungal infections, such as fusariosis
(Tortorano et al, 2012). False-positive GM can also be found
in BAL samples obtained using specific lavage solutions, such
as PlasmalyteTM (Hage et al, 2007), and may also be due to
blood products (Martın-Rabadan et al, 2012). Systemic anti-
fungal prophylaxis with a mould-active azole, such as
posaconazole, also reduces the reliability of the Aspergillus
GM test (Duarte et al, 2014). A significant decline in GM
OD indices was noted to result after storage of serum sam-
ples, but not BAL samples, so that the time from taking a
blood sample to testing should be minimized (Johnson et al,
2013).
Details on antigen testing for fungal infection other than
aspergillosis have been reviewed elsewhere (Ruhnke et al,
2012).
Studies on panfungal or Aspergillus-specific PCR assays
indicate that BAL samples may be superior to blood samples,
particularly when patients are receiving systemic antifungal
therapy (Spiess et al, 2003; Musher et al, 2004). PCR also
appears useful for lung biopsy specimens in addition to
histopathology and culture as it allows identification of the
pathogen (Rickerts et al, 2007). The lack of standardization of
PCR for blood and BAL samples was the primary reason for
not incorporating these assays in the European Organization
for Research and Treatment of Cancer (EORTC)/Mycoses
Study Group (MSG) definitions for invasive fungal diseases.
However, progress is being made by the European Aspergillus
PCR Initiative (http://www.eapcri.eu), and a cogent argument
has recently been published for now including PCR in the
EORTC/MSG definitions (White et al, 2015). It also seems
likely that PCR will be incorporated into diagnostic work-ups
for LI alongside thoracic CT scans, serology and conventional
microbiology from blood and BAL samples (White et al,
2015). The combination of Aspergillus PCR and GM in BAL
samples enhances diagnosis because the detection of both GM
and PCR make the diagnosis of pulmonary aspergillosis highly
likely, as has been confirmed by meta-analyses (Avni et al,
2012). Nonetheless, previous exposure to antifungal therapy
may reduce the sensitivity of quantitative PCR assays as well as
Aspergillus GM tests (McCulloch et al, 2012).
Legionella pneumophila serogroup 1 antigen
Nosocomial legionellosis among patients with cancer is fortu-
nately very rare though a single centre report in 2007 recom-
mended that a test for Legionella be included in the
differential diagnosis (Gudiol et al, 2007). Testing urine for
Legionella pneumophila serogroup 1 antigen helps to make a
rapid diagnosis but there are no proper clinical studies to
support routine testing.
Can I rely on biomarkers such as C-reactive
protein, procalcitonin or Interleukin 6?
Pro-inflammatory serum markers, such as C-reactive protein
(CRP), interleukin 6 (IL6), interleukin 8 (IL8), tumour
necrosis factor-alpha and procalcitonin (Robinson et al,
2011) have been evaluated, but the results are very heteroge-
neous, making a valid conclusion impossible. These markers
have not yet been studied prospectively in febrile neutropenic
patients with LI. In clinical practice, the serial measurement
of CRP and IL6 typically parallels the clinical course of infec-
tion and can be used to guide therapeutic decisions together
with clinical and imaging findings. Persistent fever, progres-
sive or newly emerged LI and rising pro-inflammatory
parameters typically indicate the need to change the antimi-
crobial treatment regimen (Robinson et al, 2011).
Procalcitonin is most useful for its negative predictive
value, as repeated failure to detect the biomarker in the con-
text of LI, fever and high inflammatory markers (CRP, IL6)
despite broad-spectrum antimicrobial treatment suggests the
infiltrate may be due to the underlying haematological malig-
nancy, and therefore a reason to start chemotherapy (Bele
et al, 2011).
Practical clinical management in neutropenic
patients
An algorithm for the clinical management of febrile neu-
tropenic patients with LI has been proposed in a recent
guideline by the Infectious Diseases Working Party of the
German Society of Haematology and Medical Oncology
(Maschmeyer et al, 2015). Figure 1 depicts a clinical pathway
reflecting these recommendations.
Diagnostic procedures
In patients with AML or MDS undergoing aggressive myelo-
suppressive chemotherapy expecting severe neutropenia last-
ing ≥10 d, serial monitoring of Aspergillus GM from blood
samples is recommended. If patients with fever of unknown
origin do not respond to an empirical first-line therapy with
an antipseudomonal beta-lactam antibiotic after 72–96 h,
they should undergo thorough physical re-examination,
imaging and microbiological diagnostics including a (mostly
native, i.e., without contrast media) thoracic CT scan. When
LI are present and/or Aspergillus GM is positive, non-inva-
sive diagnostic tests should be repeated and bronchoscopy
and BAL using a standardized protocol (Sampsonas et al,
2011) be arranged within a maximum of 24 h. Microbiological
Review
ª 2016 John Wiley & Sons Ltd 183
British Journal of Haematology, 2016, 173, 179–189
laboratory work-up of BAL samples should be started within
4 h. Recommended routine microbiological procedures are
listed in Table II. Additional assays may be added, e.g. molecu-
lar tests for respiratory viruses. In individual cases when pneu-
monia has been acquired before hospitalization, invasive
procedures, such as open lung or percutaneous core needle
biopsy, should be considered in patients with undetermined LI
who urgently require histological identification while bron-
choscopy and BAL have failed.
Antimicrobial therapy in patients without microbiological
proof
Considering the dismal prognosis of febrile neutropenic
patients with LI not treated promptly with an appropriate
antimicrobial regimen, it is recommended to start therapy on
the basis of clinical, imaging and/or laboratory findings
indicative of a particular infection in patients at risk for, but
without proof of this infection. The type of underlying
malignancy or immunosuppression has an instrumental
impact on the selection of antimicrobial agents suitable for
systemic therapy. In patients without a conclusive microbio-
logical finding and a lack of response to antimicrobial treat-
ment, re-assessment including thoracic CT scan and
eventually also bronchoscopy and BAL should be arranged
after 7 d.
Severely neutropenic AML patients with LI
Clinical outcome of proven invasive mould infection
(aspergillosis or mucormycosis) in neutropenic patients is
poor (Lin et al, 2001), so that early mould-active antifungal
treatment should be added to a broad-spectrum anti-pseudo-
monal beta-lactam in patients whose LI do not have the typi-
cal radiological pattern of PcP or lobar bacterial pneumonia
(Maschmeyer et al, 2015). It has been shown that patients
with invasive aspergillosis treated with voriconazole or lipo-
somal amphotericin B had superior response and survival
rates when treated early vs. later in the course of the disease.
In patients pre-treated with voriconazole or posaconazole for
systemic antifungal prophylaxis, in whom a breakthrough fil-
amentous fungal pneumonia is presumed, antifungal drug
levels should be checked, invasive diagnostic procedures be
taken into consideration, and antifungal treatment be
switched to liposomal amphotericin B.
In patients who have a thoracic CT scan suggesting PcP
and a rapid and otherwise unexplained rise of serum lactate
dehydrogenase, prompt start of high-dose co-trimoxazole is
recommended (see below). BAL will remain positive for P.jir-
ovecii over several days despite appropriate antimicrobial
therapy (Roger et al, 1998). This recommendation, however,
is only valid for patients who did not receive anti-Pneumo-
cystis prophylaxis.
In this group of patients, antiviral agents, glycopeptides,
fluoroquinolones or macrolide antibiotics should not be rou-
tinely given without a convincing diagnosis from clinically
significant samples.
Patients undergoing autologous haematopoietic stem cell
transplantation (AHSCT)
Patients undergoing high-dose chemotherapy and AHSCT
have a low risk of fungal pneumonia (Post et al, 2007).
Therefore, early antifungal therapy is not recommended. If
myeloma patients have been pre-treated with bortezomib, or
if total body irradiation, alemtuzumab, anti-thymocyte glob-
ulin or fludarabine has been used for conditioning, CMV
disease may be considered (Fassas et al, 2001; Ljungman
et al, 2005; Marchesi et al, 2014) and BAL checked for this
Fig 1. Algorithm for the clinical management of febrile neutropenic high-risk adult haematology patients with lung infiltrates (outside allogeneic
haematopoietic stem cell transplantation). CT, pulmonary computerized tomography; MRI, pulmonary magnetic resonance imaging; BAL, bron-
choalveolar lavage.
Table II. Standard programme for microbiological work-up of BAL
samples.
1 Cytospin preparations (May-Gr€unwald Giemsa) for microscopy
2 Gram stain
3 M. tuberculosis PCR
4 PCR for Pneumocystis jirovecii; quantitative if positive
5 Calcofluor white or equivalent (fungi, Pneumocystis jirovecii)
6 Direct immunofluorescence test for Pneumocystis jirovecii
(confirmatory)
7 Aspergillus antigen (Galactomannan Sandwich ELISA)
8 Bacterial and fungal cultures
PCR, polymerase chain reaction; ELISA, enzyme-linked immunosor-
bent assay.
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pathogen. A positive rapid culture or ‘immediate early anti-
gen’ should prompt antiviral treatment (Konoplev et al,
2001). Importantly, the quantitative measurement of CMV
copies in blood samples does not correlate with the risk of
CMV pneumonia (Ng et al, 2005). First-choice antiviral
treatment options are foscarnet or ganciclovir. The latter
may cause critical myelosuppression, while (reversible)
nephrotoxicity is the typical side effect of foscarnet.
Antimicrobial treatment in patients with
documented pathogens
Complicated bacterial pneumonias
Antimicrobial treatment of pneumonia caused by bacteria
not typically susceptible to standard broad-spectrum beta-
lactam antibiotics must be individualized. Apart from a criti-
cal discussion of the causative role of a pathogen isolated
from a diagnostic sample (see above), in vitro susceptibility
patterns and pharmacokinetic aspects (penetration to lung
tissue, possible inactivation by surfactant) must always be
included in this selection. In patients with multi-resistant
gram-negative pathogens, aerosolized colistin has been suc-
cessfully used as part of the antimicrobial strategy. Stenotro-
phomonas maltophilia rarely causes pneumonia in
haematological patients and is more frequently associated
with blood stream infections in case of an infected venous
access. Treatment recommendations for some selected bacte-
rial pneumonias are listed in Table III.
Treatment of fungal pneumonia
Aspergillus species and Mucorales are the typical pathogenic
fungi causing LI in severely neutropenic patients. Candida
spp. are frequently isolated from respiratory tract samples,
but represent the cause of LI only in rare cases of dissemi-
nated Candida fungaemia with haematogenous spread to the
lungs (Kontoyiannis et al, 2002). Updated recommendations
for the treatment of documented mucormycosis are provided
in evidence-based guidelines (Mousset et al, 2013; Cornely
et al, 2014; Schelenz et al, 2015). First-line treatment of inva-
sive pulmonary aspergillosis is intravenous voriconazole
(6 mg/kg every 12 h day 1, 4 mg/kg every 12 h thereafter) or
liposomal amphotericin B (3 mg/kg/d), while for mucormy-
cosis (zygomycosis), liposomal amphotericin B at a dose of
≥5 mg/kg/d is preferred. Most patients need more than 7–
10 d of full-dose antifungal therapy to show clinical
improvement (defervescence, decreasing inflammatory
parameters, declining dyspnoea, better oxygenation), whereas
CT scans taken after the first week of treatment often show
an increasing volume of LI (Caillot et al, 2001). Antifungal
treatment should not be changed at this point, unless new LI
emerge at previously normal pulmonary sites and clinical
deterioration is obvious. A second infection, immune recon-
stitution syndrome, infiltrates caused by the underlying
malignancy or toxic side effects from cancer treatment
should be revisited (Segal et al, 2008).
Treatment of Pneumocystis pneumonia (PcP)
If PcP is suspected, treatment with co-trimoxazole (trimetho-
prim/sulfamethoxazole; TMP/SMX) at a dosage of TMP 15–
20 mg/kg plus SMX 75–100 mg/kg/d should be initiated after
BAL or induced sputum samples have been obtained. Treat-
ment delay may enhance mortality (Guo et al, 2014). Blood
gas analysis should be done before the start of antimicrobial
therapy. If oxygen partial pressure is ≥70 mm Hg or alveo-
lar-arterial oxygen difference <45 mm Hg, upfront oral
Table III. Treatment recommendations for selected bacterial pneumonias.
Pathogen First-line antimicrobial agent Comment
Pseudomonas aeruginosa Piperacillin  tazobactam
Imipenem-cilastatin
Meropenem
Ceftazidime
Cefepime
Combination with aminoglycoside or ciprofloxacin may
be considered depending upon local resistance patterns
Escherichia coli, Klebsiella spp. or Serratia spp. with
extended-spectrum beta-lactamase (ESBL) production
Imipenem-cilastatin
Meropenem
Ertapenem
Ertapenem is not active against Pseudomonas aeruginosa
Multi-resistant gram-negative bacilli, such as
Acinetobacter baumannii
Colistin
Fosfomycin
Tigecycline
Individual decision required
Stenotrophomonas maltophilia High-dose co-trimoxazole In-vitro susceptibility testing may not reliably predict
clinical efficacy (Carroll et al, 1998)
Staphylococcus aureus (oxacillin-susceptible; MSSA) Flucloxacillin
Oxacillin
Vancomycin inferior (McDanel et al, 2015)
Staphylococcus aureus (oxacillin-resistant; MRSA) Vancomycin
Teicoplanin
Linezolid
Linezolid may cause thrombocytopenia
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therapy may be considered, otherwise intravenous treatment
is indicated. Treatment should be continued for at least
2 weeks. Clinical improvement is expected after 5–8 d, other-
wise a second infection should be considered and diagnostic
procedures be repeated. If TMP/SMX is not tolerated or inef-
fective, clindamycin (600 mg three times daily or 450 mg
four times daily) plus primaquine (30 mg/d orally) appear to
be the most effective option (Smego et al, 2001). Other
potential salvage regimens include atovaquone oral suspen-
sion (750 mg twice daily orally with meal) or intravenous
pentamidine (4 mg/kg/d). Subsequently, patients should be
given secondary prophylaxis with TMP/SMX 160/800 mg
given orally on 3 d per week or monthly pentamidine inhala-
tion at a dose of 300 mg. In patients with respiratory failure,
the use of systemic corticosteroids is controversial, as recent
(non-randomized) studies did not show a clinical benefit
(Moon et al, 2011) or were associated with increased mortal-
ity (Lemiale et al, 2013).
Should I start G-CSF in critically ill neutropenic
patients with LI?
A clear benefit from the adjunctive administration of granu-
locyte colony-stimulating factor (G-CSF) (or granulocyte-
macrophage colony-stimulating factor, which is no longer
available in some European countries) in terms of response
or survival rates has not been demonstrated. Hence, the use
of these drugs is not recommended. Indeed, there have been
reports of pulmonary function deteriorating after treatment
with G-CSF (Karlin et al, 2005).
Should I refer leukaemia patients with acute
respiratory failure to the intensive care unit?
In contrast to widespread opinions, neutropenic patients
with respiratory failure may have a favourable outcome
under appropriate intensive care including mechanical venti-
lation (Maschmeyer et al, 2003), even if invasive aspergillosis
is identified as the underlying complication. A particular
problem arises in patients whose clinical condition deterio-
rates due to haematopoietic recovery. This may happen in
one-third of patients with LI emerging during neutropenia,
especially in those with acute leukaemia and previous severe
neutropenia lasting for more than 10 d, and result in acute
respiratory distress syndrome. It is important not to misin-
terpret this worsening as a failure of antimicrobial therapy
and consequently switch to irrational antimicrobial polyphar-
macotherapy (drug combinations), but rather optimize sup-
portive care and try to lead the patient through this critical
period of immune recovery.
How long should antimicrobial treatment be
continued?
There are very sparse data on the duration of antimicrobial
treatment in patients with LI who have responded to this
treatment, so that decisions on the duration of treatment are
influenced by the nature of the pneumonia and the results of
an interim response assessment. In patients with PcP,
2–3 weeks are recommended (see above), for bacterial pneu-
monia a resolution of clinical and laboratory signs of active
infection should be documented (typically after 10–14 d of
treatment), and for CMV pneumonia, 2–4 weeks of treat-
ment appear sufficient. With respect to their high risk of
relapse, patients with invasive pulmonary mould infection
should receive systemic antifungal treatment until
haematopoietic recovery and regression of clinical and radio-
logical signs of infection.
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